October 2, 2025

Supplementary Figure S1 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Puntos clave

Higher adjusted hazard ratios indicate differing overall survival between brcaalt and no brcaalt groups.
Time to castrate-resistance is notably affected by brcaalt status during treatment with arpi.
Patients with brcaalt show distinct treatment outcomes compared to those without alterations in prostate cancer therapies.
ARPI and taxane treatments demonstrate varying effectiveness based on brcaalt and overall survival metrics.

Resumen

Outcomes on ARPI or taxane by BRCAalt status. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Chehade et al. (Wed,) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21ae6 https://doi.org/https://doi.org/10.1158/1078-0432.30255502

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar